Skip to content

Ana Maria Arance

Hospital Clínic de Barcelona

2 papers in the Anchorcite directory, published between 2014 and 2015, cited 11,682 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations

    BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…

  2. Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations

    BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…

Metadata from OpenAlex (CC0).